Browsing byAuthorGallego-Ortega, D

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 55  next >
Issue DateTitleAuthor(s)
2023-03-29A Method for Rapid, Quantitative Evaluation of Particle Sorting in Microfluidics Using Basic Cytometry Equipment.Salomon, R; Razavi Bazaz, S; Li, W; Gallego-Ortega, D; Jin, D; Warkiani, ME
2017-11A mutation in the viral sensor 2'-5'-oligoadenylate synthetase 2 causes failure of lactation.Oakes, SR; Gallego-Ortega, D; Stanford, PM; Junankar, S; Au, WWY; Kikhtyak, Z; von Korff, A; Sergio, CM; Law, AMK; Castillo, LE; Allerdice, SL; Young, AIJ; Piggin, C; Whittle, B; Bertram, E; Naylor, MJ; Roden, DL; Donovan, J; Korennykh, A; Goodnow, CC; O'Bryan, MK; Ormandy, CJ
2017-10-03A RhoA-FRET Biosensor Mouse for Intravital Imaging in Normal Tissue Homeostasis and Disease Contexts.Nobis, M; Herrmann, D; Warren, SC; Kadir, S; Leung, W; Killen, M; Magenau, A; Stevenson, D; Lucas, MC; Reischmann, N; Vennin, C; Conway, JRW; Boulghourjian, A; Zaratzian, A; Law, AM; Gallego-Ortega, D; Ormandy, CJ; Walters, SN; Grey, ST; Bailey, J; Chtanova, T; Quinn, JMW; Baldock, PA; Croucher, PI; Schwarz, JP; Mrowinska, A; Zhang, L; Herzog, H; Masedunskas, A; Hardeman, EC; Gunning, PW; Del Monte-Nieto, G; Harvey, RP; Samuel, MS; Pajic, M; McGhee, EJ; Johnsson, A-KE; Sansom, OJ; Welch, HCE; Morton, JP; Strathdee, D; Anderson, KI; Timpson, P
2017-11-07Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer.Valdés-Mora, F; Gould, CM; Colino-Sanguino, Y; Qu, W; Song, JZ; Taylor, KM; Buske, FA; Statham, AL; Nair, SS; Armstrong, NJ; Kench, JG; Lee, KML; Horvath, LG; Qiu, M; Ilinykh, A; Yeo-Teh, NS; Gallego-Ortega, D; Stirzaker, C; Clark, SJ
2022-05-03Activation of the viral sensor oligoadenylate synthetase 2 (Oas2) prevents pregnancy-driven mammary cancer metastases.Ho, W-HJ; Law, AMK; Masle-Farquhar, E; Castillo, LE; Mawson, A; O'Bryan, MK; Goodnow, CC; Gallego-Ortega, D; Oakes, SR; Ormandy, CJ
2021Advancements in 3D Cell Culture Systems for Personalizing Anti-Cancer Therapies.Law, AMK; Rodriguez de la Fuente, L; Grundy, TJ; Fang, G; Valdes-Mora, F; Gallego-Ortega, D
2022-07ALTEN: A High-Fidelity Primary Tissue-Engineering Platform to Assess Cellular Responses Ex Vivo.Law, AMK; Chen, J; Colino-Sanguino, Y; Fuente, LRDL; Fang, G; Grimes, SM; Lu, H; Huang, RJ; Boyle, ST; Venhuizen, J; Castillo, L; Tavakoli, J; Skhinas, JN; Millar, EKA; Beretov, J; Rossello, FJ; Tipper, JL; Ormandy, CJ; Samuel, MS; Cox, TR; Martelotto, L; Jin, D; Valdes-Mora, F; Ji, HP; Gallego-Ortega, D
2017-11-16Andy's Algorithms: new automated digital image analysis pipelines for FIJI.Law, AMK; Yin, JXM; Castillo, L; Young, AIJ; Piggin, C; Rogers, S; Caldon, CE; Burgess, A; Millar, EKA; O'Toole, SA; Gallego-Ortega, D; Ormandy, CJ; Oakes, SR
2022-06Author Correction: Homeostatic IL-13 in healthy skin directs dendritic cell differentiation to promote TH2 and inhibit TH17 cell polarization.Mayer, JU; Hilligan, KL; Chandler, JS; Eccles, DA; Old, SI; Domingues, RG; Yang, J; Webb, GR; Munoz-Erazo, L; Hyde, EJ; Wakelin, KA; Tang, S-C; Chappell, SC; von Daake, S; Brombacher, F; Mackay, CR; Sher, A; Tussiwand, R; Connor, LM; Gallego-Ortega, D; Jankovic, D; Le Gros, G; Hepworth, MR; Lamiable, O; Ronchese, F
2013-09BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer.Stone, A; Cowley, MJ; Valdes-Mora, F; McCloy, RA; Sergio, CM; Gallego-Ortega, D; Caldon, CE; Ormandy, CJ; Biankin, AV; Gee, JMW; Nicholson, RI; Print, CG; Clark, SJ; Musgrove, EA
2020-05Capillary-assisted microfluidic biosensing platform captures single cell secretion dynamics in nanoliter compartments.Hassanzadeh-Barforoushi, A; Warkiani, ME; Gallego-Ortega, D; Liu, G; Barber, T
2020-02Cell Lineage Tracing Identifies Hormone-Regulated and Wnt-Responsive Vaginal Epithelial Stem Cells.Ali, A; Syed, SM; Jamaluddin, MFB; Colino-Sanguino, Y; Gallego-Ortega, D; Tanwar, PS
2025-01-08Challenges in blood fractionation for cancer liquid biopsy: how can microfluidics assist?Salomon, R; Razavi Bazaz, S; Mutafopulos, K; Gallego-Ortega, D; Warkiani, M; Weitz, D; Jin, D
2017-04-18Clinical relevance of the transcriptional signature regulated by CDC42 in colorectal cancer.Valdés-Mora, F; Locke, WJ; Bandrés, E; Gallego-Ortega, D; Cejas, P; García-Cabezas, MA; Colino-Sanguino, Y; Feliú, J; Del Pulgar, TG; Lacal, JC
2024-09-26Decorin, an exercise-induced secretory protein, is associated with improved prognosis in breast cancer patients but does not mediate anti-tumorigenic tissue crosstalk in mice.Hjorth, M; Egan, CL; Telles, GD; Pal, M; Gallego-Ortega, D; Fuller, OK; McLennan, ED; Gillis, RD; Oh, TG; Muscat, GEO; Tegegne, S; Mah, MSM; Skhinas, J; Estevez, E; Adams, TE; McKay, MJ; Molloy, M; Watt, KI; Qian, H; Gregorevic, P; Cox, TR; Hojman, P; Midtgaard, J; Christensen, JF; Friedrichsen, M; Iozzo, RV; Sloan, EK; Drew, BG; Wojtaszewski, JFP; Whitham, M; Febbraio, MA
2019-01-01Droplet-based single cell RNAseq tools: A practical guideSalomon, R; Kaczorowski, D; Valdes-Mora, F; Nordon, RE; Neild, A; Farbehi, N; Bartonicek, N; Gallego-Ortega, D
2015-12ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells.Gallego-Ortega, D; Ledger, A; Roden, DL; Law, AMK; Magenau, A; Kikhtyak, Z; Cho, C; Allerdice, SL; Lee, HJ; Valdes-Mora, F; Herrmann, D; Salomon, R; Young, AIJ; Lee, BY; Sergio, CM; Kaplan, W; Piggin, C; Conway, JRW; Rabinovich, B; Millar, EKA; Oakes, SR; Chtanova, T; Swarbrick, A; Naylor, MJ; O'Toole, S; Green, AR; Timpson, P; Gee, JMW; Ellis, IO; Clark, SJ; Ormandy, CJ
2016-01-07ELF5 isoform expression is tissue-specific and significantly altered in cancer.Piggin, CL; Roden, DL; Gallego-Ortega, D; Lee, HJ; Oakes, SR; Ormandy, CJ
2020-01-02ELF5 modulates the estrogen receptor cistrome in breast cancer.Piggin, CL; Roden, DL; Law, AMK; Molloy, MP; Krisp, C; Swarbrick, A; Naylor, MJ; Kalyuga, M; Kaplan, W; Oakes, SR; Gallego-Ortega, D; Clark, SJ; Carroll, JS; Bartonicek, N; Ormandy, CJ
2013-11ELF5, normal mammary development and the heterogeneous phenotypes of breast cancerGallego-Ortega, D; Oakes, SR; Lee, HJ; Piggin, CL; Ormandy, CJ